Pierre-Jean, our study director, is actually in Cambridge to visit the MRC Laboratory of Molecular Biology.  LMB is a research institute dedicated to the understanding of important biological processes at the levels of atoms, molecules, cells and organisms. You should known it because Richard Henderson, the 2017 Nobel Prize for Chemistry, is from the the LMB’s Structural Studies Division !

If you want talk about high content screening, and discover HCS Pharma services, you can contact him to book a small interview before is return to France !

It was a real pleasure to be in the « High-Content and Phenotypic Screening » meeting in Cambridge. We were invited by our partner Molecular Devices to give a talk during the “User meeting Molecular Devices” about our vision of 3D culture in phenotypic screening and the impact of new technologies. We also presented a poster about “Neurotoxicity assay on 2D and 3D culture using High Content Screening technology”.

You can find our presentation here and our poster here.

It was a good opportunity to present our new laboratories in Lille and the future HCS Pharma robotic platform built by Molecular Devices with two ImageXpress Micro confocal.

After a short presentation of our services, we explained our implication in the two research projects InnovCell 3D and Chopin. Many people were interested by these programs,

We also shared again our uses of new technologies like augmented reality, virtual reality or machine learning, like in the previous forum LABO. We noticed that the 3D segmentation is a problem for almost everybody. It will be one of our goal for 2017 to check as many segmentation solutions as possible and to build our own in relation with MetaXpress and Molecular Devices.

If you have any questions, if you want to share about this topic, don’t hesitate to contact us !

High Content & Phenotypic Screening 2016
Date: Tuesday, 10 May 2016 – Wednesday, 11 May 2016
Location: Cambridge, UK

“Phenotypic screening was the primary mechanism of drug discovery for decades before the development of genomics enabled target selection, so this revival of interest in phenotypic screening is really a return to the past. …But of the 50 first-in-class new molecular entities (NMEs) approved for clinical use, 28 (56%) were discovered using a phenotypic approach, while 17 (34%) were target-based discoveries. … Phenotypic screening has received quite a bit of attention, and has become an increasingly popular approach, due to recent analyses showing that more NMEs have been discovered using phenotypic assays.

If you want to know more about this topic, I recommand to read this recent article : “Bridget K. Wagner (2015): The resurgence of phenotypic screening in drug discovery and development, Expert Opinion on Drug Discovery, DOI: 10.1517/17460441.2016.1122589“, where I took these sentences or going to the event on this topic :”High Contet & Phenotypic Screening 2016” in UK.

I hope to be there. We are preparing another one in Rennes in France with ELRIGfr association. Annoucement will followed in the next few weeks! Thus don’t forget to follow us!

%d bloggers like this: